Compare PLUR & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUR | DARE |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 24.3M |
| IPO Year | 2001 | 2014 |
| Metric | PLUR | DARE |
|---|---|---|
| Price | $3.53 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $10.00 |
| AVG Volume (30 Days) | 10.6K | ★ 71.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,336,000.00 | ★ $2,807,885.00 |
| Revenue This Year | $97.38 | $3,843.33 |
| Revenue Next Year | $293.97 | $8,700.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $1.58 |
| 52 Week High | $7.13 | $9.19 |
| Indicator | PLUR | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 32.02 |
| Support Level | $3.50 | N/A |
| Resistance Level | $3.85 | $1.86 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 53.44 | 4.76 |
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.